Obesity as a Risk Factor for Inflammatory Breast Cancer

Beth Overmoyer, MD;

Obesity as a Risk Factor for Inflammatory Breast Cancer

December 17, 2014

By Beth Overmoyer, MD

Publication

Article

Special ReportsBreast Cancer (Issue 1)

Volume 1

Issue 1

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.

<<<

Back to the Breast Cancer Special Report

Articles in this issue

Breast Ultrasound Added to Mammography Increases Cancer Detection

Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debuted

Anti-Androgen Not for Male Cancers Alone

Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBC

Obesity as a Risk Factor for Inflammatory Breast Cancer

Advances in the Treatment of HER2-Positive Breast Cancer

Immune Checkpoint Inhibition in Breast Cancer

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Related Content

Frontline Dato-DXd Looks Promising in NSCLC

Morgan Bayer

May 13th 2025

Article

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH

February 6th 2025

Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer

Targeted Oncology Staff

May 13th 2025

Article

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.